Our understanding of the relationship between the human body and illness is constantly evolving due to an expanding quantity of genomics data highlighting links between genetic variations and disease. However, examining genomics, which is the study of the characteristics and behavior of a person’s genes, is just the first step in understanding how diseases develop. To learn more about the human cell, researchers are now looking beyond the genome into other molecular datasets like proteins and RNA, through the field of multiomics, which looks at layering multiple datasets. Multiomics can improve researchers’ understanding of disease-causing gene variants in both common and complex disorders while identifying novel biomarkers and drug targets. 

As a field of research, multiomics is still in its infancy. However, it is growing at a rapid rate. Multiomics startups raised more than USD 600 million in combined funding from investors during the first three months of 2022. Some, like Mission Bio, have already launched proprietary multiomics platforms while others, such as Parse Biosciences, PrognomiQ, and DNAnexus, are following suit with recently raised capital. 

Multiomics is used in multiple domains, ranging from healthcare and plant science to agriculture and food biotechnology. This insight’s focus includes multiomics’ potential to disrupt the healthcare and pharmaceutical industries, the technology that laid the foundation for the field, its applications in various medical avenues, and the industry’s current landscape.